Cancer Council Australia
Larger Text Smaller Text Print

Prostate cancer



Clinical Practice Guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer

 

The Clinical Practice Guidelines: PSA Testing and Early Management of Test-Detected Prostate Cancer were developed through a partnership of the Prostate Cancer Foundation of Australia (PCFA) and Cancer Council Australia.

For the first time, these guidelines provide health professionals access to evidence-based recommendations for using the prostate specific antigen (PSA) blood test to assess prostate cancer risk and manage test-detected patients. The recommendations also cover matters such as retesting, active surveillance, watchful waiting and biopsy.

The recommendations in these guidelines are approved by the CEO of the National Health and Medical Research Council (NHMRC). In granting approval, NHMRC is satisfied that the guideline recommendations are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practicing in an Australian health care setting.

The guidelines were launched in January 2016.

 

Clincial Practice Guidelines

Consumer guidelines

To obtain a free copy, of Localised Prostate Cancer: a guide for men and their families 2010 and Advanced Prostate Cancer: a guide for men and their families 2009, please call Cancer Council 13 11 20.


This page was last updated on: Wednesday, January 20, 2016